In search of CML stem cells' deadly weakness

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) is a myeloproliferative disorder driven by the BCR-ABL fusion oncogene.
• BCR-ABL protein's tyrosine kinase activity leads to excessive myeloid cell production.
• Current tyrosine kinase inhibitors are effective but cannot eliminate quiescent leukemic stem cells, hindering CML eradication.

Purpose of the Study:

• To review current research in CML.
• To identify and discuss emerging therapeutic targets with the potential to eradicate CML, including leukemic stem cells.

Main Methods:

• Literature review of current research in CML.
• Analysis of novel molecular targets investigated for their role in myeloid leukemia pathogenesis.

Main Results:

• Tyrosine kinase inhibitors have advanced CML therapy but are limited by their inability to target quiescent leukemic stem cells.
• Several novel targets are under investigation for their potential to modulate CML pathogenesis and eradicate the disease.

Conclusions:

• Eradicating CML requires targeting primitive, quiescent leukemic stem cells.
• Emerging targets such as miRNAs, IL1RAP, BMI1, FOXOs, PML, PP2A, and JAK2 show promise for developing curative CML therapies.